Using stereotactic radiotherapy for treating thoracic tumors
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
This study tests if a special type of radiation therapy can safely treat chest tumors that are 5cm or smaller while protecting nearby healthy tissue.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05349552 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety and efficacy of stereotactic body radiation therapy (SBRT) for malignant tumors located in different areas of the chest. It categorizes tumors based on their proximity to critical structures such as the chest wall and bronchial tree, aiming to understand how these factors influence treatment outcomes and toxicity. The research focuses on patients with tumors that are 5cm or smaller and assesses the effectiveness of SBRT in providing localized control while minimizing damage to surrounding healthy tissue. By analyzing various tumor types, the study seeks to optimize treatment protocols for thoracic cancers.
Who should consider this trial
Good fit: Ideal candidates include patients with a pathological diagnosis of malignant tumors located in specific areas of the chest, with lesions measuring 5cm or less.
Not a fit: Patients with poor pulmonary function, severe underlying health conditions, or those unable to cooperate with treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the safety and effectiveness of radiotherapy for patients with thoracic malignancies.
How similar studies have performed: Other studies have shown promising results with SBRT in lung cancer treatment, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathological diagnosis was malignant tumor. * The location of the target lesion belongs to one of five types and the lesion diameter is ≤ 5cm. * There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment. * KPS\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy. Exclusion Criteria: * Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment. * The general condition is poor, and the expected survival time is less than 3 months. * Psychiatric patients or poor compliance, unable to cooperate to complete treatment. * For other reasons, the researcher believes that it is not suitable to participate in this trial.
Where this trial is running
Beijing, Beijing Municipality
- Peking University Third Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Zhe Ji, M.D.
- Email: aschoff@163.com
- Phone: 008618710002823
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.